Testing the drug paxalisib in people whose central nervous system lymphoma has come back
Original title: Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSL
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is a middle stage study, so the drug has been given to people before but is still being tested.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study is testing a drug called paxalisib in people with primary central nervous system lymphoma that came back or did not respond to earlier treatment.
Who this trial is for. This trial is for people with primary central nervous system lymphoma, called PCNSL. That is a lymphoma that starts in the central nervous system. The title says it is for people whose lymphoma has come back or did not respond to earlier treatment. The trial is testing a drug called paxalisib, also known as GDC-0084, as a possible treatment.
Where it stands. There are no results yet. The trial is looking at whether paxalisib can help people with this kind of lymphoma. The source does not report any findings. So we do not know yet if it works or how well it is tolerated.
What this means, and what it doesn't
What it could mean: Right now this drug is being tested, not offered as regular care. If you or someone you care for has PCNSL that came back or did not respond to treatment, you could ask your care team about this trial. They can tell you if it might be a fit and what other options you have.
What it doesn't mean: This does not mean paxalisib works for PCNSL. A trial is a test, not a proven treatment. Joining a study is not a guarantee that you will be helped. It is not a promise of a cure. The results are not in, so no one can say yet what this drug does for people with this lymphoma.
Source: ClinicalTrials.gov, August 5, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.